The 111In ibritumomab tiuxetan and 90Y ibritumomab tiuxetan were prepared from FDA-approved kits supplied by Biogen/IDEC. The kits were designed to provide a 185 MBq (5 mCi) 111In dose for imaging or a maximum of 1.18 GBq (32 mCi)/kit of 90Y. To administer therapeutic doses greater than 1.18 GBq, additional kits were required, each supplying 1.18 GBq of 90Y activity. A commercial nuclear pharmacy formulated the doses (Cardinal Health, Dublin, OH, USA). Given that the patients had received weekly infusions of rituximab for each of the 4 weeks prior to the dosimetric dose, no unlabeled rituximab was administered immediately prior to infusion of the dosimetric or the therapeutic doses. This is in contrast to the FDA-approved clinical therapy approach, in which an infusion of 250 mg/m2 rituximab is given over 1–2 h immediately prior to administration of each of the dosimetric or therapeutic doses. In all cases, patients were treated as outpatients, as their radiation emissions (bremsstrahlung), as assessed by measured radiation levels at one meter following therapy, allowed for them to remain as outpatients in compliance with state and NRC radiation safety guidelines. No post-treatment dosimetric imaging was performed.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.